Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Cocrystal Pharma ( (COCP) ).
On June 25, 2025, Cocrystal Pharma, Inc. held its 2025 Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and strategic plans. Stockholders elected six board members for a one-year term, ratified Weinberg & Company as the independent accounting firm for 2025, and approved the 2025 Equity Incentive Plan. Due to sufficient votes, the proposal to adjourn the meeting was deemed unnecessary.
The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.
Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Average Trading Volume: 20,090
Technical Sentiment Signal: Sell
Current Market Cap: $15.16M
For detailed information about COCP stock, go to TipRanks’ Stock Analysis page.